This is a routine director 144 filing with negligible market impact. The small share count and derivative-based acquisition suggest compensation-related liquidity, not information-motivated selling. No actionable trade signal.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $29.82entry
- T+1 · 5mo ago +3.76%α +3.21% · $30.94
- T+5 · 5mo ago +8.28%α +7.85% · $32.29
- T+20 · 4mo ago +2.35%α +0.46% · $30.52
- T+60 · 2mo ago −23.88%α −27.70% · $22.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Daniella Beckman filed a Form 144 notice of intent to sell 4,446 shares of Tango Therapeutics common stock, with an approximate market value of $133,380 based on a $30.00 reference price. The shares being sold amount to less than 0.01% of the company's $4.6B market cap and represent stock acquired through option exercise and restricted stock vesting. This is a routine and immaterial insider sale by a director, consistent with compensation-related share liquidation.
Key Facts
- Director Daniella Beckman filed Form 144 to sell 4,446 shares of Tango Therapeutics
- Approximate market value of proposed sale: $133,380
- Shares acquired via stock option exercise (914 shares) and restricted stock vesting (3,532 shares from 2017 grants)
- Sale represents ~0.003% of $4.6B market cap, immaterial dilution concern
- Filing is a notice of intent to sell under Rule 144, not a completed transaction
Financial Impact
Proposed sale of 4,446 shares worth approximately $133,380, less than 0.01% of market cap
Risk Factors
- Form 144 signals intent to sell but does not guarantee the sale will execute
- Insider could be diversifying holdings, though amount is trivial relative to total position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005901 |
| Document: 0001950047-26-005901-index.html | 0001950047-26-005901 |
| Document: 0001950047-26-005901.txt | 0001950047-26-005901 |
Track record
27 reports on TNGX
3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers